CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Other Events

14

CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Other Events

Item8.01.

Other Events

On June19, 2017, CRISPR Therapeutics AG (the Company) announced
that Chinas State Intellectual Property Office has granted a
patent broadly covering the Companys in-licensed gene editing
technology. A copy of the press release announcing the grant of
the patent is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.


Item9.01.
Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not
filed:


Exhibit No.


Description

99.1 Press Release by CRISPR Therapeutics AG, dated June19, 2017



CRISPR Therapeutics AG Exhibit
EX-99.1 2 d417591dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China     •   Patent includes CRISPR/Cas9 gene editing methods and compositions for use in any non-cellular and cellular setting,…
To view the full exhibit click here
About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

An ad to help with our costs